Drug Trial Radar · NCT05603910
Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Apr 15, 2023
Primary completion
Apr 15, 2029
Study completion Apr 15, 2034
Sponsor
- Lead sponsor
- Aaron WolfsonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research study is to see if it is feasible to combine a fixed dose of pembrolizumab and a daily dose of oral lenvatinib, along with daily treatments of an abbreviated course of pelvic external beam radiation therapy, to support cancer cells in multiplying and spreading to other body sites.
Conditions
- Recurrent Endometrial Carcinoma
- Unresectable Endometrial Carcinoma
Interventions
LenvatinibDrug
Lenvatinib will be self-administered orally (PO) by participants in a 3+3 escalation/de-escalation design. Participants will receive one of the following four dose levels: * Dose level 1: 4 mg * Dose level 2: 8 mg * Dose level 3: 12 mg (Starting dose) * Dose level 4: 16 mg
PembrolizumabDrug
Pembrolizumab 200 mg will be administered intravenously (IV) once on Days 1, 22 and 43.
Hypofractionated External Beam Radiation TherapyRadiation
Whole pelvic HypoFx EBRT consisting of 16 fractions of radiation given at a dose of 2.5 Gy per fraction for a total dose of 40.0 Gy. A pelvic boost HypoFx EBRT consisting of 7 fractions of radiation given at a dose of 2.5 Gy per fraction for a total dose of 17.5 Gy, delivered to site(s) of gross disease of at least 1.0 cm in size.
High-Dose Rate (HDR) BrachytherapyRadiation
Vaginal high-dose rate (HDR) brachytherapy administered per standard of care (SoC) techniques.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended Phase 2 Dose (RP2D) of LenvatinibTime frame: Up to 12 weeks
- Number of Participants Experiencing Treatment-Related Toxicity: Dose-Limiting Toxicities (DLTs)Time frame: Up to 12 weeks
- Number of Participants Experiencing Treatment-Related Toxicity: Adverse Events (AEs)Time frame: Up to 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Miami
Miami, Florida · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.